Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey
| العنوان: | Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey |
|---|---|
| المؤلفون: | Tae-Yun Sung, Hong Seuk Yang, Jae-Ho Lee, Ha Jung Kim, Jae Moon Choi, Yong Beom Kim, Jung Woo Han, Yong Seop Shin, Jin Sun Kim |
| المصدر: | Anesthesia and Pain Medicine |
| بيانات النشر: | Korean Society of Anesthesiologists, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Neuromuscular Blockade, business.industry, Neuromuscular Physiology and Pharmacology, Pyridostigmine bromide, General Medicine, Neuromuscular Blocking Agents, Neuromuscular monitoring, Vial, Sugammadex, Neostigmine, Pyridostigmine, Neuromuscular blocking agents, Clinical Research, Anesthesia, medicine, Rocuronium, business, medicine.drug |
| الوصف: | Background Neuromuscular blocking agents (NMBAs) and neuromuscular monitoring in anesthetic management are integral for endotracheal intubation, better visualization of the surgical field, and prevention of residual neuromuscular blockade and pulmonary complications. Sugammadex is a drug that reduces risk of residual neuromuscular blockade, with more rapid recovery compared to anticholinesterase. The purpose of this study was to investigate current usage status of NMBAs and antagonist with neuromuscular monitoring, among anesthesiologists in Korea. Methods Anesthesiologists working in Korea were invited to participate in an online survey via email January 2-February 28, 2018. The questionnaire consisted of 45 items, including preferred NMBAs, antagonists, neuromuscular monitoring, and complications related to the use sugammadex. A total of 174 responses were analyzed. Results Rocuronium was a commonly used NMBA for endotracheal intubation (98%) of hospitals, and maintenance of anesthesia (83.3%) in of hospitals. Sugammadex, pyridostigmine, and neostigmine were used in 89.1%, 87.9%, and 45.4% of hospitals. Neuromuscular monitoring was employed in 79.3% of hospitals; however only 39.7% of hospitals used neuromuscular monitoring before antagonist administration. Usual dosage range of sugammadex was 2.1-4 mg/kg in 35.1% of hospitals, within 2 mg/kg in 34.5% of hospitals, and 1 vial regardless of body weight in 22.4% of hospitals. Sugammadexrelated complications were encountered by 14.9% of respondents. Conclusions This survey indicates several minor problems associated with the use of antagonists and neuromuscular monitoring. However, most anesthesiologists appear to have appropriate information regarding the usage of NMBAs and sugammadex. |
| اللغة: | English |
| تدمد: | 2383-7977 1975-5171 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdfaa0068990b1f415cdf316b025f53aTest http://europepmc.org/articles/PMC7713803Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fdfaa0068990b1f415cdf316b025f53a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23837977 19755171 |
|---|